{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:01:45Z","timestamp":1791273705960,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The presence of \u2265 15% bone marrow (BM) ring sideroblasts (RS) and &lt; 5% blasts is required for a diagnosis of refractory anemia with ring sideroblasts. We examined the phenotypic and prognostic relevance of this \u201c15%\u201d RS threshold in 200 patients with myelodysplastic syndromes (MDS) without excess blasts and with \u2265 1% RS. The impact of RS% was assessed both as a continuous and categorical variable: &lt; 5% (n = 56), 5%-14% (n = 32), 15%-50% (n = 79), and &gt; 50% (n = 33). RS% correlated (P &lt; .05) directly with age, platelet count, transfusion dependency, BM cellularity, and mutant SF3B1 and inversely with hemoglobin level, multilineage dysplasia, and high-risk karyotype; but did not correlate with IDH mutations. At a median follow-up of 33 months, 156 (73%) deaths and 24 (12%) leukemic transformations were documented. Neither univariate nor multivariable analysis showed significant effect for RS% on overall or leukemia-free survival, suggesting the limited prognostic value of quantifying BM RS in MDS.<\/jats:p>","DOI":"10.1182\/blood-2012-03-415356","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T06:07:46Z","timestamp":1335506866000},"page":"5674-5677","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Prognostic irrelevance of ring sideroblast percentage in World Health Organization\u2013defined myelodysplastic syndromes without excess blasts"],"prefix":"10.1182","volume":"119","author":[{"given":"Mrinal M.","family":"Patnaik","sequence":"first","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Hematopathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna H.","family":"Sulai","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Hodnefield","sequence":"additional","affiliation":[{"name":"Hematopathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Knudson","sequence":"additional","affiliation":[{"name":"Cytogenetics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Cytogenetics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Divisions of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111808260382700_B1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3324\/haematol.13405","article-title":"Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.","volume":"93","author":"Mufti","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111808260382700_B2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2011.044628","article-title":"Ring sideroblasts and sideroblastic anemias.","volume":"96","author":"Cazzola","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2019111808260382700_B3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"2019111808260382700_B4","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111808260382700_B5","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.89.9.4028","article-title":"Enzymatic defect in \u201cX-linked\u201d sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency.","volume":"89","author":"Cotter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111808260382700_B6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ng.359","article-title":"Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia.","volume":"41","author":"Guernsey","year":"2009","journal-title":"Nat Genet"},{"issue":"8","key":"2019111808260382700_B7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.tig.2008.05.008","article-title":"Iron-sulfur cluster biogenesis and human disease.","volume":"24","author":"Rouault","year":"2008","journal-title":"Trends Genet"},{"issue":"5","key":"2019111808260382700_B8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/hmg\/8.5.743","article-title":"Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA\/A).","volume":"8","author":"Allikmets","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"15","key":"2019111808260382700_B9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808260382700_B10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111808260382700_B11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.","volume":"26","author":"Visconte","year":"2011","journal-title":"Leukemia"},{"issue":"7367","key":"2019111808260382700_B12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia.","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111808260382700_B13","doi-asserted-by":"crossref","first-page":"e1970","DOI":"10.1371\/journal.pone.0001970","article-title":"The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.","volume":"3","author":"Boultwood","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"2019111808260382700_B14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2005-12-4769","article-title":"Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.","volume":"108","author":"Pellagatti","year":"2006","journal-title":"Blood"},{"key":"2019111808260382700_B15","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0145-2126(11)70016-9","article-title":"Revised International Prognostic Scoring System (IPSS-R) developed by the International Working Group for Prognosis in MDS (IWG-PM).","volume":"35","author":"Greenberg","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"2019111808260382700_B16","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111808260382700_B17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2019111808260382700_B18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared with either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"26","key":"2019111808260382700_B19","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes.","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808260382700_B20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111808260382700_B21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.hoc.2010.02.001","article-title":"The genetic basis of myelodysplastic syndromes.","volume":"24","author":"Bejar","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2019111808260382700_B22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes.","volume":"29","author":"Bejar","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808260382700_B23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"issue":"14","key":"2019111808260382700_B24","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5674\/1497581\/zh802412005674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5674\/1497581\/zh802412005674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:49:07Z","timestamp":1574084947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/24\/5674\/30309\/Prognostic-irrelevance-of-ring-sideroblast"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-415356","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}